Doubts about DOT: antiretroviral therapy for resource-poor countries

被引:45
作者
Liechty, CA
Bangsberg, DR
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, EPI Ctr, Div Infect Dis, San Francisco, CA 94110 USA
[2] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco Gen Hosp AIDS Program, San Francisco, CA 94110 USA
[3] Acad Alliance, Kampala, Uganda
关键词
HIV antiretroviral therapy; Africa; resource-poor; adherence; resistance; directly observed therapy;
D O I
10.1097/00002030-200306130-00013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Directly observed therapy programs developed for tuberculosis (TB) have been suggested as a model for the provision of HIV medications in resource-poor countries in order to ensure adherence and prevent drug resistance. Methods: Opinions were formed based on a review of scientific literature regarding the effectiveness of witnessed dosing in directly observed TB therapy programs, adherence to HIV antiretroviral therapy in resource-rich and resource-poor settings, relationship between adherence and HIV antiretroviral drug resistance, HIV viral load and risk of HIV transmission, and stigmatization concerns related to HIV and TB in resource-poor settings. Results/conclusions: We suggest that the enthusiasm for HIV directly observed therapy programs is premature based on: equivocal evidence that witnessed dosing is superior to self administered therapy; mistaken assumptions that resource-poor countries are a 'special case' with respect to adherence; possible paradoxical impact of good adherence on HIV drug resistance; unproven efficacy of antiretroviral therapy in preventing HIV transmission; and potential stigmatization of daily antiretroviral dosing. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1383 / 1387
页数:5
相关论文
共 61 条
[1]   The era of adherence to HIV therapy [J].
Altice, FL ;
Friedland, GH .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (06) :503-505
[2]  
[Anonymous], 1997, TREATM TUB GUID NAT
[3]  
[Anonymous], BOSTON GLOBE 0607
[4]  
ANZAMA R, 2001, 1 IAS C HIV PATH TRE
[5]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[6]  
BANGSBERG D, IN PRESS AIDS
[7]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[8]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[9]  
BANGSBERG DR, 2002, 11 HIV DRUG RES WORK
[10]   THE DUAL EPIDEMICS OF TUBERCULOSIS AND AIDS - ETHICAL AND POLICY ISSUES IN SCREENING AND TREATMENT [J].
BAYER, R ;
DUBLER, NN ;
LANDESMAN, S .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1993, 83 (05) :649-654